Oxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2004-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.5.11.2351PMID 15500382
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Anticholinergic drugs versus placebo for overactive bladder syndrome in adults.

  2006cited by this paper
• Treatment of detrusor instability with oxybutynin rectal suppositories

  2005influential reference
• Economics of Incontinence

  2005influential reference
• Economic costs of urinary incontinence

  2005cited by this paper
• Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial.

  2003cited by this paper
• Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence

  2003cited by this paper
• Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence.

  2003cited by this paper
• Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects.

  2003cited by this paper
• The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society.

  2003cited by this paper
• The standardisation of terminology in nocturia: Report from the standardisation sub‐committee of the International Continence Society

  2002cited by this paper
• Tolterodine: As effective but better tolerated than oxybutynin in Asian patients with symptoms of overactive bladder

  2002cited by this paper
• The Mucosa of the Small Intestine

  2002cited by this paper
• New perspectives on the overactive bladder: pharmacokinetics and bioavailability.

  2002cited by this paper
• Overview consensus statement.

  2002cited by this paper
• The standardisation of terminology of lower urinary tract function: Report from the standardisation sub‐committee of the International Continence Society

  2002cited by this paper
• Efficacy, Safety, and Tolerability of Extended‐Release Once‐Daily Tolterodine Treatment for Overactive Bladder in Older versus Younger Patients

  2002cited by this paper
• The standardization of terminology in nocturia: report from the standardization subcommittee of the International Continence Society

  2002cited by this paper
• YM905 appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a european placebo- and tolterodinge-conrolled, phase-II, dose-finding study

  2002cited by this paper
• Treatment of Overactive Bladder with Once-daily Extended-release Tolterodine or Oxybutynin: The Antimuscarinic Clinical Effectiveness Trial (ACET)

  2002cited by this paper
• Current and future pharmacological treatment for overactive bladder.

  2002cited by this paper
• Efficacy and safety of transdermal oxybutynin in patients with urge and mixed urinary incontinence.

  2002cited by this paper
• A randomized controlled trial of tolterodine and oxybutynin on tolerability and clinical efficacy for treating Chinese women with an overactive bladder

  2002cited by this paper
• A comparison of newer drug treatments for URINARY INCONTINENCE

  2002cited by this paper
• Effects of Tolterodine, Trospium Chloride, and Oxybutynin on the Central Nervous System

  2001cited by this paper
• Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

  2001cited by this paper
• Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study.

  2001cited by this paper
• How widespread are the symptoms of an overactive bladder and how are they managed? A population‐based prevalence study

  2001cited by this paper
• The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro.

  2001cited by this paper
• Tolterodine: superior tolerability than and comparable efficacy to oxybutynin in individuals 50 years old or older with overactive bladder: a randomized controlled trial.

  2001cited by this paper
• Association between oxybutynin and neuropsychiatric adverse effects not confirmed in daily practice

  2001cited by this paper
• Efficacy, tolerability and safety profile of propiverine in the treatment of the overactive bladder (non-neurogenic and neurogenic)

  2001cited by this paper
• Effect of OROS controlled-release delivery on the pharmacokinetics and pharmacodynamics of oxybutynin chloride.

  2001cited by this paper
• A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.

  2001influential reference
• A randomized controlled trial comparing the efficacy of controlled‐release oxybutynin tablets (10 mg once daily) with conventional oxybutynin tablets (5 mg twice daily) in patients whose symptoms were stabilized on 5 mg twice daily of oxybutynin

  2000cited by this paper
• Urinary incontinence in both sexes: Prevalence rates and impact on quality of life and sexual life

  2000cited by this paper
• Urinary Incontinence: Does it Increase Risk for Falls and Fractures?

  2000cited by this paper
• MUSCARINIC RECEPTOR ANTAGONISTS IN THE TREATMENT OF OVERACTIVE BLADDER

  2000cited by this paper
• Overactive Bladder and Its Treatments Consensus Conference. London, United Kingdom, July 4, 1999.

  2000cited by this paper
• Absorption of oxybutynin from vaginal inserts: drug blood levels and the response of the rabbit bladder.

  2000cited by this paper
• A pharmacoeconomic evaluation of two new products for the treatment of overactive bladder.

  2000cited by this paper
• The role of M2‐muscarinic receptors in mediating contraction of the pig urinary bladder in vitro

  2000cited by this paper
• Extended-Release Oxybutynin

  2000influential reference
• Treatment of overactive bladder with modified intravesical oxybutynin chloride

  2000cited by this paper
• Trospium chloride: an effective option for medical treatment of bladder overactivity.

  2000cited by this paper
• M3 muscarinic receptors but not M2 mediate contraction of the porcine detrusor muscle in vitro.

  2000cited by this paper
• The Association of Depressive Symptoms and Urinary Incontinence Among Older Adults

  2000cited by this paper
• INTRODUCTION: OVERACTIVE BLADDER AND ITS TREATMENTS

  2000cited by this paper
• Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.

  2000cited by this paper
• Pharmacokinetics of an Oral Once‐a‐Day Controlled‐Release Oxybutynin Formulation Compared with Immediate‐Release Oxybutynin

  1999influential reference
• Evaluation of a new once-daily formulation of oxbutynin for the treatment of urinary urge incontinence. Ditropan XL Study Group.

  1999cited by this paper
• Evaluation of a new once-daily formulation of oxybutynin for the treatment of urinary urge incontinence

  1999cited by this paper
• Glutamatergic and dopaminergic contributions to rat bladder hyperactivity after cerebral artery occlusion.

  1999cited by this paper
• Clinical Efficacy and Safety of Tolterodine Compared to Oxybutynin and Placebo in Patients with Overactive Bladder

  1999cited by this paper
• Patient-oriented outcomes with once-daily oxybutynin for urge incontinence

  1999cited by this paper
• A placebo‐controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutynin in patients with urgency and urge incontinence

  1999cited by this paper
• Function, signal transduction mechanisms and plasticity of presynaptic muscarinic receptors in the urinary bladder.

  1999cited by this paper
• Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence. OROS Oxybutynin Study Group.

  1999cited by this paper
• Identification of Medications That Cause Cognitive Impairment in Older People: The Case of Oxybutynin Chloride

  1998cited by this paper
• Economic costs of urinary incontinence in 1995.

  1998cited by this paper
• A Review of the Quality-of-Life Aspects of Urinary Urge Incontinence

  1998cited by this paper
• Pharmacologic therapy for urinary incontinence and voiding dysfunctions.

  1998cited by this paper
• Pharmacological characterization of muscarinic receptors in rabbit isolated iris sphincter muscle and urinary bladder smooth muscle

  1998cited by this paper
• Urethral afferent nerve activity affects the micturition reflex; implication for the relationship between stress incontinence and detrusor instability.

  1998influential reference
• The Association of Urinary Incontinence with Poor Self‐Rated Health

  1998cited by this paper
• Variation in Estimates of Urinary Incontinence Prevalence in the Community: Effects of Differences in Definition, Population Characteristics, and Study Type

  1998cited by this paper
• Tolterodine--a new bladder-selective antimuscarinic agent.

  1998cited by this paper
• Efficacy and safety of two doses of tolterodine versus placebo in patients with detrusor overactivity and symptoms of frequency, urge incontinence, and urgency: urodynamic evaluation

  1998cited by this paper
• Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder.

  1998cited by this paper
• The Overactive Bladder: From Basic Science to Clinical Management Consensus Conference. Proceedings. London, England, June 29, 1997.

  1997cited by this paper
• Comparison of a 10‐mg controlled release oxybutynin tablet with a 5‐mg oxybutynin tablet in urge incontinent patients

  1997cited by this paper
• Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: a pooled analysis.

  1997cited by this paper
• A myogenic basis for the overactive bladder.

  1997cited by this paper
• Lesson of the week: Oxybutynin and cognitive dysfunction

  1997cited by this paper
• Introduction to the overactive bladder: From basic science to clinical management

  1997cited by this paper
• Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder.

  1996cited by this paper
• Urinary Incontinence in Adults: Acute and Chronic Management

  1996cited by this paper
• Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia.

  1996cited by this paper
• Intravesical oxybutynin for spinal cord injury patients

  1996cited by this paper
• Clinical and urodynamic effects of propiverine in patients suffering from urgency and urge incontinence. A multicentre dose-optimizing study.

  1995cited by this paper
• Oxybutynin

  1995cited by this paper
• Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins.

  1995cited by this paper
• Pharmacology of incontinence.

  1995cited by this paper
• Trospium chloride versus oxybutynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyper-reflexia.

  1995cited by this paper
• Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial

  1995cited by this paper
• The use of intravesical oxybutynin chloride in patients with detrusor hypertonicity and detrusor hyperreflexia.

  1994cited by this paper
• Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients.

  1994cited by this paper
• Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder

  1994cited by this paper
• Intravesical oxybutynin chloride: experience with 42 patients.

  1993cited by this paper
• Intravesical oxybutynin chloride and clean intermittent catheterisation in patients with neurogenic vesical dysfunction and decreased bladder capacity.

  1993cited by this paper
• The use of intravesical oxybutynin chloride in children with neurogenic bladder.

  1991cited by this paper
• Randomized, double-blind, multicenter trial on treatment of frequency, urgency and incontinence related to detrusor hyperactivity: oxybutynin versus propantheline versus placebo.

  1991cited by this paper
• Control of detrusor hyperreflexia by the intravesical instillation of oxybutynine hydrochloride

  1991cited by this paper
• Psychosocial Impact of Urinary Incontinence in the Community‐Dwelling Population

  1990cited by this paper
• The treatment of detrusor instability in postinenopausal women with oxybutynin chloride: a double blind placebo controlled study

  1990cited by this paper
• The treatment of detrusor instability in postmenopausal women with oxybutynin chloride: a double blind placebo controlled study

  1990cited by this paper
• Prevalence and Incidence of Urinary Incontinence in Community‐Dwelling Populations

  1990cited by this paper
• Topical oxybutynin chloride for relaxation of dysfunctional bladders.

  1989cited by this paper
• Oxybutinin versus propantheline in the management of detrusor instability. A patient‐regulated variable dose trial

  1989cited by this paper
• Oxybutynin: is it safe?

  1988cited by this paper
• Conservative therapy of frequency, urgency and urge incontinence: A double-blind clinical trial of flavoxate hydrochloride, exybutinin chloride, emepronium bromide and placebo

  1987influential reference

• Efficacy of atomoxetine plus oxybutynin in the treatment of obstructive sleep apnea with moderate pharyngeal collapsibility

  2022cites this paper
• Medical Management of Benign Prostatic Hyperplasia

  2019cites this paper
• Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.

  2015cites this paper
• Intravesical drug delivery for dysfunctional bladder

  2013cites this paper
• Development of long-acting bioadhesive vaginal gels of oxybutynin: formulation, in vitro and in vivo evaluations.

  2013cites this paper
• Conclusive Identification of the Oxybutynin-Hydrolyzing Enzyme in Human Liver

  2012cites this paper
• Intravesical therapy for lower urinary tract symptoms

  2012cites this paper
• Conclusive Identification of the Oxybutynin-hydrolyzing Enzyme in Human Liver

  2012cites this paper
• Urinary Incontinence and Overactive Bladder: A Review

  2009cites this paper
• Efficacy and Safety of Propiverine Hydrochloride 40mg in Treatment of Overactive Bladder : Prospective, Multicenter, Observational study.

  2008cites this paper
• Endoskopie, minimal invasive chirurgische und navigierte Verfahren in der Urologie

  2008cites this paper
• Antimuscarinic drugs for the treatment of overactive bladder: are they really all the same? - A comparative review of data pertaining to pharmacological and physiological aspects

  2007cites this paper
• Local drug delivery to bladder using technology innovations.

  2006cites this paper
• Current and emerging investigational medical therapies for the treatment of overactive bladder

  2006influential citation
• Intravesical Therapy of Interstitial Cystitis

  2005cites this paper